Table 4.

Effect of ivabradine therapy with regard to NYHA class, 6MWT distance, HR and Borg scale before and after 6MWT.

Group 2		Baseline	End of follow-up	Test value	p	Significance
NYHA class	1	0 (0.0)	7 (36.8)	35.264a	<0.001	HS
	2	0 (0.0)	11 (57.9)
	3	14 (70.0)	1 (5.3)
	4	6 (30.0)	0 (0.0)
HR before	Mean ± SD	94.50 ± 12.13	72.37 ± 6.53	8.340b	<0.001	HS
	Range	80–130	60–85
BORG dyspnea before	Median (IQR)	3 (3–4)	2 (1–2)	3.919	<0.001	HS
	Range	2–5	1–3
BORG fatigue before	Median (IQR)	3 (3–4)	2 (1–2)	3.923c	<0.001	HS
	Range	2–5	1–3
6MWT distance	Mean ± SD	135.50 ± 60.91	254.21 ± 6.21	10.899b	<0.001	HS
	Range	20–230	150–360
Premature termination of 6MWT	Negative	16 (80.0)	19 (100.0)	4.234a	0.039	S
	Dyspnea	4 (20.0)	0 (0.0)
HR after	Mean ± SD	120.75 ± 15.75	88.42 ± 9.73	7.843b	<0.001	HS
	Range	100–150	70–110
Borg dyspnea after	Median (IQR)	7 (6–8)	5 (4–6)	3.750c	<0.001	HS
	Range	5–10	3–7
Borg fatigue after	Median (IQR)	7 (6–8)	5 (4–6)	3.750c	<0.001	HS
	Range	5–10	3–7

Data are presented as n (%), mean ± SD, or range.

6MWT = 6-minute walking test distance; HR = heart rate; HS = highly significant; IQR = interquartile range; MLWHFQ = Minnesota Living with Heart Failure Questionnaire; NS = non-significant; NYHA = New York Heart Association; S = significant.

^aChi-square test.

^bIndependent t test.

^cFisher exact test.